Inhaled Prophylactic Heparin in Ventilator Associated Pneumonia Prevention- A randomised controlled trial of nebulised unfractionated heparin versus saline or usual care to prevent the development of VAP in invasively ventilated patients

A/Prof Robert Boots0 个研究点目标入组 914 人开始时间: 2012年1月9日最近更新: 2020年1月13日

试验速览

暂无简介。

•1.Pregancy
•2.Aged less than 18 years of age
•3.Patients with previous known sensitivity to heparin (any formulation or route) including heparin induced thrombocytopenia
•4.Any contraindication to routine prophylaxis for deep vein thrombosis using subcutaneous heparin
•5.Presence of a coagulopathy including platelet dysfunction thought to be of clinical significance of any type on admission considered to be a contraindication to routine prophylaxis for deep vein thrombosis using subcutaneous heparin
•6.Patients receiving any other type of systemic full anticoagulation
•7.Patients transferred from another intensive care unit with more than 48 hours of mechanical ventilation before entering into the present study.
•Patients receiving routine subcutaneous thromboembolism prophylaxis (= 15,000/units day) or heparin as part of continuous dialysis therapy where systemic anticoagulation is not required are suitable for inclusion but enrolled patients must be withdrawn from the study upon the need for systemic full anticoagulation or bleeding considered due to the effects of the inhaled heparin by the treating consultant.

发起方

A/Prof Robert Boots